Clinical Trial Update: Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population [Phase 2]

View source ↗

Summary

Phase 2 single-dose study evaluating four doses of LAS100977 in chronic obstructive pulmonary disease has completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• LAS100977

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED | Results posted: 2017-04-10